Share Name Share Symbol Market Type Share ISIN Share Description
Scapa Group LSE:SCPA London Ordinary Share GB0007281198 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  +4.80p +1.13% 428.80p 151,747 16:35:29
Bid Price Offer Price High Price Low Price Open Price
424.20p 426.80p 430.00p 418.60p 423.60p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 291.50 28.80 15.40 27.8 658.6

Scapa (SCPA) Latest News

More Scapa News
Scapa Takeover Rumours

Scapa (SCPA) Share Charts

1 Year Scapa Chart

1 Year Scapa Chart

1 Month Scapa Chart

1 Month Scapa Chart

Intraday Scapa Chart

Intraday Scapa Chart

Scapa (SCPA) Discussions and Chat

Scapa Forums and Chat

Date Time Title Posts
08/6/201816:56Scapa onwards and upwards1,010
05/10/200615:18Scapa.......nobrainer or should I scarper?76
16/3/200613:43SCAPA upwards147

Add a New Thread

Scapa (SCPA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-08-21 15:52:46428.6089381.45O
2018-08-21 15:40:00428.551,2005,142.61O
2018-08-21 15:39:39430.003,73216,047.60O
2018-08-21 15:35:29428.805,00621,465.73UT
2018-08-21 15:29:55425.40138587.05AT
View all Scapa trades in real-time

Scapa (SCPA) Top Chat Posts

Scapa Daily Update: Scapa Group is listed in the Chemicals sector of the London Stock Exchange with ticker SCPA. The last closing price for Scapa was 424p.
Scapa Group has a 4 week average price of 403p and a 12 week average price of 401p.
The 1 year high share price is 510p while the 1 year low share price is currently 397p.
There are currently 153,602,138 shares in issue and the average daily traded volume is 116,601 shares. The market capitalisation of Scapa Group is £658,645,967.74.
typo56: Interesting, Numis make no mention of the accident. Chosing to ignore or consider insignificant? They are, of course, the house broker! "Scapa Group's share price has fallen 18% since the company's trading statement last week and Numis says this makes the stock attractive and raises its recommendation to buy from add. The brokerage considers this an excellent entry point into a company that, since 2013, has delivered Ebita compound annual growth rate of 20%. Numis says further margin gains can be expected in the Industrials unit, as there is an increasingly favorable global GDP growth and construction outlook. The brokerage adds that the Healthcare division is well-positioned at a time of increased outsourcing, in a market that is reportedly growing at a rate of 9%. Shares are down 3.8% at 406 pence."
robow: Lovely write up here from Questor in the Daily Telegraph this morning. A 90-year-old manufacturer that was “at death’s door” a few years ago has transformed itself into a specialist, high-margin business with enviable returns on capital and cash generation – yet its valuation remains reasonable. Scapa originally made consumables for the paper industry. But it got into difficulty in the Nineties and sold that entire business to a German rival. “It was at death’s door at that point,” said Keith Ashworth-Lord, whose SDL UK Buffettology fund includes Aim-quoted Scapa as a top-10 holding. “Once it had sold the paper arm it was essentially left with a business that made industrial and electrical tapes, which are relatively unspecialised and low-margin products. Scapa at first did little to develop the tapes business and the group remained a bit of a mess.” All that changed in 2009 with the appointment as chief executive of Heejae Chae, previously of Volex, the cables group, said Ashworth-Lord. “Chae basically turned the business upside down,” the fund manager said. “He attacked the manufacturing base and started to take the products upmarket.” This involved a shift in the group’s focus from low-margin industrial tapes to more hi-tech areas such as wound dressings. “Then the company got even cleverer, making products that require ‘clean room’ technology, for example, and started to become a preferred partner to the likes of Johnson & Johnson and Smith & Nephew,” Ashworth-Lord said. The company’s transformation was largely achieved by the acquisition of three healthcare companies. “The areas it operates in now are more value-added – they involve providing solutions rather than just selling a product,” the fund manager said. “Scapa has always made double-digit margins in healthcare; they are currently about 16pc. “Meanwhile, margins in the legacy industrial business have also been improved: they are 11.5pc this year, up from about 3pc in 2011.” The industrial side still has the higher turnover but because of the difference in margins the healthcare business contributes more to the group’s profits. Scapa has improved efficiency in the industrials arm by consolidating its output into fewer factories, but has done so “really smartly”, Ashworth-Lord said. “It has maximised the value of redundant sites. For example, it demolished a factory in Switzerland, then cleared the site, got planning permission and sold it for housing. The result was a profit on the book value of the site. There is probably room for more consolidation of this type. The company does everything in a measured way.” He said the transformation of the company’s operations had a huge impact on its financial success, adding: “Returns on capital were once about 3pc; now they are 11pc, although returns on the capital most recently deployed are in the mid-20s. Cash conversion last year was 95pc. That sort of cash generation means that acquisitions can be funded out of cash flow.” Net debts are accordingly relatively modest at £16m, compared with net assets of about £100m. “That puts ‘gearing’; at 16pc – it’s not an over-leveraged balance sheet at all. All told, this is the kind of business I love.” The stock’s price-to-earnings ratio, based on last year’s “adjusted̶1; profits, is 32.1, but growth is 30pc-40pc annually: earnings per share were 3.6p in 2013, then 4.4p in 2014, 7.7p in 2015, 10.5p in 2016 and 14.8p last year. “It’s not dirt cheap, but you are paying a fair price for a quality business,” Ashworth-Lord said. “I have absolute faith in this company – the management knows its stuff, the business is really firing, I never have to worry about profit warnings. In the end it will probably be acquired but for now it is a core holding.” As an Aim-quoted trading business, Scapa should qualify for inheritance tax exemption if held for at least two years. Questor says: buy Ticker: SCPA Share price at close: 475.8p
robow: Numis upgrades Scapa on ‘significant’ potential Numis has upgraded chemicals group Scapa (SCPA) on prospects for ‘significant upside’ over the next two years. Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘add’ with a target price of 485p on the stock after the share price ‘softened since the publication of a strong set of interim results with trading profit up 22%’. ‘We see plenty of scope for further margin improvement,’ he said. ‘Mergers and acquisitions remain a key driver with two scalable platforms that can deliver both revenue and cost synergies. We see plenty of upside to mid-term forecasts and move back to “add” with around 10% upside to our target price.’ He added that ‘over the next two years we see far more significant upside to our 800p per share bull case’. The shares rose 2.1% to 441.5p yesterday.
grabster: Although the share price has multiplied a very impressive eightfold in 5 years, it can sometimes track sideways for up to a year at times. Hence definitely one for the longterm investor (2-3 years minimum) prepared to wait for the ongoing climb. I hold none at the moment but it remains on my watchlist to buy into sometime.
3rd eye: Scapa Group plc 27.1% Potential Upside Indicated by Berenberg Posted by: Katherine Hargreaves 15th April 2016 Scapa Group plc using EPIC/TICKER code LON:SCPA has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Berenberg. Scapa Group plc are listed in the Basic Materials sector within AIM. Berenberg have set their target price at 300 GBX on its stock. This is indicating the analyst believes there is a potential upside of 27.1% from the opening price of 236 GBX. Over the last 30 and 90 trading days the company share price has increased 31.2933 points and increased 49 points respectively. Scapa Group plc LON:SCPA has a 50 day moving average of 204.10 GBX and a 200 day moving average of 202.42 GBX. The 1 year high share price is 245 GBX while the 52 week low is 156.73 GBX. There are currently 150,942,761 shares in issue with the average daily volume traded being 361,839. Market capitalisation for LON:SCPA is £363,394,697 GBP.
felix99: hope so! Looking good so far for one anyway if you believe the share price movement
cockneyrebel: I see Arden have upped their forecasts already to 2.7p eps for the year done and 3.6p eps for the coming year. £18m net cash and no debt means a share price of 30p with it strippped out. Reckon those forecasts will be tweaked up more at the results in May too imo. CR
spooky: Big volume and a rising share price,always a winning combination :-o)
jdung: at more one month, the share price trade very small size, and not move.. still need waiting, because no "AT" trade, up or down? not sure...
cockneyrebel: Below is part of what Hanover have announced in respect of Spirent, have a read, very interesting and tells you where RNO and SCPA are going too imo CR Sherborne Investors' background Sherborne has its antecedents in the mid 1970's when some of our current principals became involved in what today is commonly known as private equity. The distinctive characteristic of our approach was and remains a focus on turnaround investing, which involves improving the underlying business operations of companies in which we invest. In recent years, we have extended our turnaround investing activities from private equity to publicly quoted companies. The model in both cases is the same, except that where we invest as a minority in publicly quoted companies, we seek to do this by offering our participation on the board, rather than through ownership and control of the company. In the case of companies such as Spirent, which we believe have the potential to increase their profits substantially but which have underperformed for an extended period of time, our firm's approach provides current shareholders with a new alternative. In the absence of an operational turnaround, shareholders in underperforming companies can choose to continue with the existing situation and hope for the best, or to sell their shares at a loss. In some cases a buyer for the whole company, frequently a private equity firm, may emerge offering a modest premium to a depressed share price. Ironically, a private equity buyer is quite likely to do some of the things that Sherborne Investors may propose to be done and subsequently to sell the company back to public shareholders at a profit. Our proposal is intended to afford to you, as an existing shareholder of Spirent, the opportunity to restore or improve the value of your shares rather than turning that opportunity over to someone else. UK turnaround investment examples Turnaround investing is something that the principals in our firm have been doing for more than 25 years, but it is somewhat novel in the public market in the United Kingdom. While our approach may be unfamiliar, it is by no means unproven. Many shareholders may be aware of earlier public investments in the UK with which certain of our firm's principals were associated, as follows: * 4imprint Group plc shares rose from 51.5p per share to 144.0p per share in the 12 month period from the announcement of our acquisition of a significant holding in July 2003 to the date of our nominee's withdrawal from the chairmanship of the company; and * Shares in Elementis Group plc rose from 31.9p per share at the time our holdings were publicly disclosed in January 2005 to 90.3p per share in September 2006 when our nominee resigned the chairmanship of the company. These returns were the result of significant earnings improvements during the periods of our involvement. We are pleased to be able to say that, as of today's date, both companies have continued to do well. While there can be no guarantee of a similar outcome at Spirent, our analysis indicates that there is significant potential for operating improvements, and for advances in the share price, even from current levels. Our turnaround investment approach is proven in practice but nonetheless remains somewhat novel for public companies. Accordingly, we would like to correct some misapprehensions about what we are proposing.
Scapa share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180821 23:32:33